Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Neoantigen DNA Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy
TypeinterventionalSponsorWashington University School of MedicineRan2018 to 2022Enrolled15ConditionsPancreatic Cancer, Pancreas Cancer, Cancer of the PancreasArmsPersonalized neoantigen DNA vaccine, TDS-IM Electrode Array System, Peripheral blood draws
A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy
TypeinterventionalSponsorWashington University School of MedicineRan2020 to 2023Enrolled12ConditionsPancreas Cancer, Pancreatic Cancer, Cancer of the PancreasArmsNeoantigen Peptide Vaccine, Poly ICLC, Blood for immune monitoring
3 · Its place in the literature
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The record
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
36 authors.
Felicia Zhang PerkinsDepartment of Surgery, Washington University School of Medicine, Saint Louis, MO, USA.ORCID 0000-0002-0057-5870
Xiuli ZhangDepartment of Surgery, Washington University School of Medicine, Saint Louis, MO, USA.ORCID 0009-0006-2464-5403
Yik Yeung Lawrence YuDepartment of Surgery, Washington University School of Medicine, Saint Louis, MO, USA.
Yilin YangDepartment of Surgery, Washington University School of Medicine, Saint Louis, MO, USA.ORCID 0000-0003-4004-5126
Darren CullinanDepartment of Surgery, Washington University School of Medicine, Saint Louis, MO, USA.
Kartik SinghalDepartment of Medicine, Washington University School of Medicine, Saint Louis, MO, USA.ORCID 0000-0002-3855-7950
Carlos A Parra-LopezUniversidad Nacional de Colombia Medical School, Department of Microbiology, Bogotá, Colombia.ORCID 0000-0002-6084-8981
Christopher A MillerDepartment of Medicine, Washington University School of Medicine, Saint Louis, MO, USA.ORCID 0000-0003-4266-6700
Binghan YanDepartment of Medicine, Washington University School of Medicine, Saint Louis, MO, USA.ORCID 0009-0003-0691-8437
Julia W AngkeowDepartment of Medicine, Washington University School of Medicine, Saint Louis, MO, USA.ORCID 0009-0002-8274-1859
Jinglun LiDepartment of Medicine, Washington University School of Medicine, Saint Louis, MO, USA.ORCID 0000-0003-1303-9345
Nancy B MyersDepartment of Surgery, Washington University School of Medicine, Saint Louis, MO, USA.ORCID 0009-0004-3556-783X
Tammi VickeryDepartment of Surgery, Washington University School of Medicine, Saint Louis, MO, USA.ORCID 0009-0005-1541-1472
John HerndonDepartment of Surgery, Washington University School of Medicine, Saint Louis, MO, USA.ORCID 0000-0002-8378-9654
Rashmi MishraDepartment of Surgery, Washington University School of Medicine, Saint Louis, MO, USA.ORCID 0009-0002-7103-9685
Stephanie MylesThe Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, Saint Louis, MO, USA.
Dominic SanfordDepartment of Surgery, Washington University School of Medicine, Saint Louis, MO, USA.
Elizabeth M JaffeeDepartment of Oncology, The Sidney Kimmel Cancer Center at Johns Hopkins and the Cancer Convergence Institute, Baltimore, MD, USA.ORCID 0000-0003-3841-6549
Daniel A LaheruDepartment of Oncology, The Sidney Kimmel Cancer Center at Johns Hopkins and the Cancer Convergence Institute, Baltimore, MD, USA.ORCID 0000-0001-6646-0200
Andrea Wang-GillamDepartment of Medicine, Washington University School of Medicine, Saint Louis, MO, USA.ORCID 0000-0003-0458-7614
Marianna B RuzinovaDepartment of Pathology and Immunology, Washington University School of Medicine, Saint Louis, MO, USA.ORCID 0000-0002-0833-8335
Ian S HagemannDepartment of Pathology and Immunology, Washington University School of Medicine, Saint Louis, MO, USA.ORCID 0000-0002-3855-9745
Sherri R DaviesDepartment of Surgery, Washington University School of Medicine, Saint Louis, MO, USA.ORCID 0000-0002-7141-8354
Timothy P FlemingNorton Thoracic Institute, St. Joseph Hospital and Medical Center, Phoenix, AZ, USA.ORCID 0000-0002-8661-1210
Shelby NamenDepartment of Radiation Oncology, Washington University School of Medicine, Saint Louis, MO, USA.ORCID 0000-0001-5006-9020
Carl J DeSelmDepartment of Radiation Oncology, Washington University School of Medicine, Saint Louis, MO, USA.ORCID 0000-0001-7645-5798
Lijin LiDepartment of Surgery, Washington University School of Medicine, Saint Louis, MO, USA.ORCID 0000-0001-6203-8854
Roheena Z PanniDepartment of Surgery, Washington University School of Medicine, Saint Louis, MO, USA.ORCID 0000-0002-8144-6869
Feng GaoDepartment of Surgery, Washington University School of Medicine, Saint Louis, MO, USA.ORCID 0000-0002-1425-1623
Kian-Huat LimDepartment of Medicine, Washington University School of Medicine, Saint Louis, MO, USA.ORCID 0000-0002-2766-200X
Obi L GriffithDepartment of Medicine, Washington University School of Medicine, Saint Louis, MO, USA.ORCID 0000-0002-0843-4271
Malachi GriffithDepartment of Medicine, Washington University School of Medicine, Saint Louis, MO, USA.ORCID 0000-0002-6388-446X
Robert D SchreiberThe Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, Saint Louis, MO, USA.ORCID 0000-0003-1590-2341
S Peter GoedegebuureDepartment of Surgery, Washington University School of Medicine, Saint Louis, MO, USA.ORCID 0000-0001-7084-3378
William G HawkinsDepartment of Surgery, Medical University of South Carolina, Charleston, SC, USA.ORCID 0000-0001-7087-3585
William E GillandersDepartment of Surgery, Washington University School of Medicine, Saint Louis, MO, USA.ORCID 0000-0002-0465-3071
Funding
Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI TIMOTHY J. EBERLEIN · 2001 to 2026
$128.0M
NATIONAL RESEARCH SERVICE AWARD-MEDICAL SCIENTISTT32GM007200 · NIGMS · WASHINGTON UNIVERSITY · PI YOKOYAMA, WAYNE M. · 1985 to 2024
$59.8M
SURGICAL ONCOLOGY TRAINING GRANTT32CA009621 · NCI · WASHINGTON UNIVERSITY · PI TIMOTHY J. EBERLEIN, William E. Gillanders · 1988 to 2026
$12.9M
Transforming Human Pancreatic Cancer Into An Immunologic DiseaseP01CA247886 · NCI · JOHNS HOPKINS UNIVERSITY · PI JAFFEE, ELIZABETH M. · 2021 to 2025
$12.7M
Washington University Paul Calabresi K12 Career Development Award for Clinical OncologyK12CA167540 · NCI · WASHINGTON UNIVERSITY · PI John F. Dipersio, Ramaswamy Govindan · 2012 to 2026
$11.7M
Washington University SPORE in Pancreatic CancerP50CA196510 · NCI · WASHINGTON UNIVERSITY · PI HAWKINS, WILLIAM G · 2016 to 2020
$10.9M
National Research Service Award-Medical ScientistT32GM154644 · NIGMS · WASHINGTON UNIVERSITY · PI Wayne M. Yokoyama · 2025 to 2026
$5.2M
Targeting Neoantigens in Triple Negative Breast CancerR01CA240983 · NCI · WASHINGTON UNIVERSITY · PI GILLANDERS, WILLIAM E., SCHREIBER, ROBERT DAVID · 2019 to 2023
$3.2M
Informatics tools for identification, prioritization and clinical application of neoantigensU01CA248235 · NCI · WASHINGTON UNIVERSITY · PI GRIFFITH, MALACHI · 2020 to 2022
Pancreatic ductal adenocarcinoma (PDAC) is unresponsive to standard immunotherapies despite harboring cancer neoantigens capable of eliciting T cell responses. We completed two phase 1 clinical trials (NCT03956056 and NCT03122106) evaluating safety and immunogenicity of synthetic long peptide (SLP) and DNA personalized cancer vaccines (PCVs). PCVs were administered after resection and adjuvant chemotherapy. Tumor/normal whole-exome sequencing, RNA sequencing, and pVACtools were used to identify and prioritize candidate PCV neoantigens. PCVs were well tolerated without any grade ≥3 adverse events. Neoantigen-specific responses were demonstrated by interferon-γ enzyme-linked immunospot and intracellular cytokine staining. Expanded T cell receptor clonotypes were sequenced and transduced into autologous peripheral blood mononuclear cells to confirm neoantigen specificity. When compared with a contemporaneous institutional propensity-matched cohort, PCV patients demonstrated a trend toward prolonged median overall survival (4.4 versus 3.5 years, log-rank
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Synthetic long peptide and DNA personalized cancer vaccines induce robust neoantigen-specific T cell responses in pancreatic cancer. · full record | OpenQuestion